biote Corp.

BTMD Healthcare Medical Care Facilities

biote Corp.’s revenue for fiscal 2025 (year ended December 2025) was $192.2 million, down 2.52% from fiscal 2024. In the quarter to June 2026, revenue fell 9.48%, EPS fell 330.0%, free cash flow fell 174.2% and total debt rose 16.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.09 0.02 −1.80%
Market cap
$39.9M
P/E
6.8×
Fwd P/E
11.0×
Dividend yield
—
F-score
7/9
Altman Z
2.65
Beneish M
−2.72
Dividend safety
n/a

Insider Decisions trades per month

Total buys 0.20
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 1 — —
Sell — — — — — — — — — — — —
Insider Ownership 18.61%

Capital & Financial Ratios $m

Market Cap 39.88
Revenue 183.53
Net Income 7.08
Free Cash Flow 17.52
Net Debt 110.33
Current Ratio 1.43
Debt/Equity (2.09) (negative: negative equity)
P/E ratio 6.81
Fwd P/E 11.00
P/S ratio 0.17
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth (96.28%) (below 0%: weak)
Next Y EPS Growth 763.64% (at or above 15%: strong)
Next Y revenue growth (7.45%) (below 0%: weak)
Next 5Y EPS Growth (12.25%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/E against its own 10 years 63.52%
10-year low 10-year high
P/S against its own 10 years 6.05%
10-year low 10-year high
EV/Sales against its own 10 years 32.34%
10-year low 10-year high
EV/FCF against its own 10 years 78.06%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 89 39 24 11
Receivables 7 8 7 8
Inventory 17 15 19 18
Other 9 6 5 6
122 68 55 43
2023 2024 2025 Q'26
Payables 4 6 7 7
ST’ Debt 6 6 6 3
Other — 25 19 3
22 52 45 30

Compound Annual Growth %

10y 5y 3y
Sales — — 5.23%
Cash Flow — 0.00% 0.00%
Earnings — — 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 45 44 — — —
’25 49 49 48 46 192
’24 47 49 51 50 197
’23 45 49 46 46 185
’22 37 41 42 44 165
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 4 (1) — — —
’25 6 7 14 8 35
’24 7 10 16 12 45
’23 13 7 0 7 27
’22 7 (29) 6 6 (9)
’21 (1) 18 6 10 34
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 (4) — — —
’25 5 5 13 5 28
’24 6 7 14 11 38
’23 13 6 0 6 24
’22 6 (29) 6 6 (11)
’21 (1) 17 5 9 30
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.06 (0.23) — — —
’25 0.37 0.10 0.22 0.06 0.74
’24 (0.06) (0.19) 0.33 0.10 0.09
’23 (0.39) (0.25) 0.24 0.18 0.13
’22 — 2.01 (1.74) 0.18 (0.12)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 9.56 2.00 2.75 3.65 2.32

Analyst estimates 2026–2028

Powerpack
High — — — — — 10.10 10.53 8.22 8.44 6.36
People
People Employees — — — — — 4 186 194 217 223
Revenue/emp, $m — — — — — 34.85 0.89 0.96 0.91 0.86
Income, $m
Income, $m Revenue — — — — — 139 165 185 197 192
Gross margin, % — — — — — 64.98 66.92 68.78 70.52 71.46
EBT — — — — 0 33 2 0 1 38
EBT margin, % — — — — 0.00 23.61 1.04 (0.07) 0.52 19.55
Net income — 0 — — 0 33 1 (3) 0 32
Depreciation — — — — — 2 3 4 4 5
Per share, $
Per share, $ Revenue — — — — 0.00 18.40 20.47 7.21 5.75 6.14
Earnings — — — — — 0.64 (0.12) 0.13 0.09 0.86
Cash flow — — — — 0.00 4.45 (1.14) 1.05 1.32 1.13
Capex — — — — 0.00 (0.50) (0.23) (0.11) (0.20) (0.22)
Free cash flow — — — — 0.00 3.95 (1.36) 0.94 1.12 0.91
Book value — — — — 0.00 0.54 (7.23) (1.42) (2.98) (1.61)
Shares, m — — — — 8 8 8 26 34 31
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.26 0.00 29.43 3.02
P/S — — — — — 0.00 0.18 0.66 1.07 0.42
P/B — — — — — 18.68 0.00 0.00 0.00 0.00
EV/Sales — — — — — 0.00 0.41 0.78 1.42 0.85
EV/FCF — — — — — 2.92 (6.20) 6.02 7.31 5.80
Cash, $m
Cash, $m Operating cash flow — — — — 0 34 (9) 27 45 35
Capex — — — — — (4) (2) (3) (7) (7)
Free cash flow — — — — 0 30 (11) 24 38 28
Balance, $m
Balance, $m Working capital — — — — 0 30 82 100 17 10
Total debt — — — — — 37 118 113 107 107
Net debt — — — — 0 10 39 24 68 83
Shareholders’ equity — — — — 0 4 (58) (37) (102) (50)
Returns, %
Returns, % ROA — — — — 0.00 119.75 (1.17) 2.48 2.27 23.52
ROIC — — — — 0.00 150.82 0.00 0.00 0.00 68.34
ROE — — — — 0.00 1,572.00 3.58 (6.99) (4.55) (35.45)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

biote Corp. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AIRS AirSculpt Technologies, Inc. $102.0M — (loss-making) — (loss-making) −2.53% (below 0%: shrinking) n/m −131.07% (below 0%: shrinking) 61.38% (0.07%) Compare
JYNT The Joint Corp. $97.7M 26.0× 16.9× +14.41% (above 0%: growing) +400.00% (above 0%: growing) +432.31% (above 0%: growing) 83.68% (2.43%) Compare
PARK Park Dental Partners, Inc. $91.3M — (loss-making) — +12.15% (above 0%: growing) −65.84% (below 0%: shrinking) −34.78% (below 0%: shrinking) 14.37% 1.90% Compare
BTMD biote Corp. $39.9M 6.8× 11.0× −9.48% (below 0%: shrinking) n/m −174.16% (below 0%: shrinking) 65.38% (7.93%)
PIII P3 Health Partners Inc. $30.1M — (loss-making) — +8.60% (above 0%: growing) n/m −272.24% (below 0%: shrinking) 22.26% 10.67% Compare
CCEL Cryo-Cell International Inc. $29.4M — (loss-making) 43.8× −0.02% (below 0%: shrinking) +77.78% (above 0%: growing) −58.37% (below 0%: shrinking) 79.38% 28.04% Compare
DCGO DocGo Inc. $27.9M — (loss-making) — (loss-making) −8.70% (below 0%: shrinking) n/m −132.28% (below 0%: shrinking) 30.52% (24.41%) Compare
PAIYY Aesthetic Medical International Hldngs Group Ltd Sponsored ADR $15.9M — (loss-making) 8.3× +25,427.42% (above 0%: growing) n/m −206.36% (below 0%: shrinking) 42.70% (1.24%) Compare
CCM Concord Medical Services Holdings Limited $10.5M — (loss-making) — (loss-making) +37.65% (above 0%: growing) n/m −281.45% (below 0%: shrinking) (13.15%) 0.00% Compare
Median of peers $29.7M — 16.9× +10.38% +77.78% −131.67% 36.61% (0.03%)

All 55 Medical Care Facilities stocks →

biote Corp. (BTMD) key facts

  • Concern: biote Corp.’s revenue for fiscal 2025 (year ended December 2025) was $192.2 million, down 2.52% from fiscal 2024.
  • biote Corp. (BTMD) is a Medical Care Facilities company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, BTMD traded at $1.09, a market capitalization of $39.9 million.
  • Return on equity was −35.5% and debt-to-equity -2.09.
  • Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 2.65 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

biote Corp. (BTMD) Latest News

5 Aug

Impact 3 · transcript

7 May

stockrow.com/BTMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com